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The mortality in acute liver failure (ALF) remains high despite
superior contemporary management. Although orthotopic liver
transplantation (OLT) is best for rescue in ALF, donor organ short-
ages and contraindications or irreversible neurological complica-
tions may restrict OLT. Therefore, alternative therapeutic
approaches for ALF are necessary. These are typically aimed at
managing complications, ameliorating inﬂammation, providing
hepatic support, and inducing liver repair/regeneration. Whether
cell therapy would offer such beneﬁts is of interest for many rea-
sons: cells from one donor could be used for several people; cryo-
preserved and banked cells could be administered rapidly; cells
could be transplanted multiple times; provision of hepatic sup-
port from transplanted cells could ‘‘bridge’’ to OLT; reseeding of
the liver with transplanted cells could promote tissue repair;
secretion of appropriate factors from transplanted cells could
aid liver regeneration, which might avoid OLT altogether; cell
therapy is technically simple and is also ‘‘reversible’’ because
the native liver need not be removed. Allogeneic hepatocytes
are normally rejected over 7–10 days but immunosuppression
might not be required for short-term cell therapies in ALF.
Recent insights into the potential of various cell types in liver
regeneration, mechanisms of liver repopulation and tissue engi-
neering support the possibility of cell therapy for ALF. New
sources of cells for transplantation, including candidate stem
cells, will expand the supply of transplantable cells.
A major question in ALF is whether one must reseed the native
liver with cells, which is difﬁcult, or whether creating a mass of
transplanted cells elsewhere in simpler ways will sufﬁce.
Here, we highlight issues in intrahepatic versus extrahepatic
transplantation of cells for ALF. Findings from animal studies
are included in this discussion.Journal of Hepatology 20
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The worldwide experience up to 2006 of hepatocyte transplanta-
tion included 37 children and adults (Table 1) [1]. We are not
aware subsequently of hepatocyte transplantation in more peo-
ple with ALF. To date, all studies have been uncontrolled. Most
cases received allogeneic adult human hepatocytes, often repeat-
edly. The routes of cell administration varied – into portal vein,
spleen or peritoneal cavity. The sample sizes were small for inter-
group comparisons. After hepatocyte transplantation, 7 of 37
cases (19%) recovered without OLT and 8 (22%) cases recovered
after OLT. Thus, hepatocyte transplantation was ‘‘successful’’ in
15 out of 37 (41%) cases.
However, critical questions were unanswered: did trans-
planted hepatocytes . . . engraft? . . . proliferate? . . . produce liver
regeneration? If so, how, and what was the fate of transplanted
cells in liver, spleen or peritoneal cavity? Understanding the
mechanistic basis of recovery after cell therapy in ALF is neces-
sary for therapeutic development. For instance, the nature of
interventions would change if liver must be reseeded with cells
compared with transplantation of cells in peritoneal cavity, since
the latter is simpler.Idiopathic 6 4 2 2 3
Mushroom 1 0 1 1
Post-surgical 1 0 1 
Total 37 10 27 7** 8***
⁄From Fisher and Strom [1].
⁄⁄Cells transplanted via portal vein (3 cases), spleen (1 case), and peritoneal cavity
(3 cases).
⁄⁄⁄Cells transplanted via portal vein (4 cases), and spleen (4 cases).
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Fig. 1. Schematic representation of principles for cell therapy in ALF. (A) Major categories of donor cells are listed. Adult cells include hepatocytes and liver sinusoidal
endothelial cells. Cells could be isolated from cadaveric, non-heart beating (NHB) or living-related donors. The challenges include limited supply of cadaveric donors.
Successful use of NHB donors will require organ procurement and cell isolation programs. Superior cryopreservation protocols are essential. Candidate stem cells include
human embryonic (hESC) or fetal cells. Adult donors types include induced pluripotent stem (iPS) cells, stem cells from discarded human livers, or stem cells from bone
marrow, blood, mesenchymal cells, adipose tissue, etc. Challenges with stem cells concern efﬁcient differentiation protocols, extent of cell differentiation, expansion of
differentiated cells in vitro, restrictions in engraftment and proliferation of cells in vivo, and mitigation of cancer risks. (B) indicates potential anatomic sites for cell
transplantation. Transplanting cells in the liver itself seems appropriate, although hepatic space is small, hepatocyte transplantation worsens liver injury, and transplanted
cells in small numbers should provide little hepatic support. By contrast, transplantation of cells into extrahepatic sites, such as peritoneal cavity, would accommodate far
larger numbers of cells. This will permit adequate hepatic support along with paracrine signaling from transplanted cells to accelerate liver regeneration. The space in an
auxiliary liver, e.g. with decellularized–recellularized matrix, should be customizable for appropriate hepatic support and paracrine signaling. (C) Desirable outcomes are
listed. ‘‘Bridge’’ to OLT or recovery without OLT will constitute good outcomes. This should concern restoration of proteins, coagulation factors and intermediary
metabolism, ammonia ﬁxation and decrease in cytokine storm, and liver regeneration, including recruitment of endogenous stem cells. Incorporating suitable drugs,
biological agents and devices should be appropriate and helpful.
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Integrating evidences from animal studies in ALF
Reseeding of the liver with transplanted cells in ALF carries lim-
itations. After hepatocyte transplantation via portal vein or
spleen, only 1–5% of the hepatocyte mass was replaced in the
liver [2]. Transplanted hepatocytes occluded portal vessels and
hepatic sinusoids, albeit temporarily, but with signiﬁcant hepatic
injury and inﬂammation [3]. Days were required for engraftment
and weeks for proliferation (to small extent) of transplanted
hepatocytes in acute liver injury [4].
By contrast, the greater space in peritoneal cavity accommo-
dated larger numbers of transplanted cells than the liver. In the
presence of scaffolds, transplanted hepatocytes engrafted in per-
itoneal cavity [5]. Transplanted cells remained in peritoneal cav-
ity without migrating elsewhere, e.g. to the liver. After cell
transplantation in peritoneal cavity in ALF, liver injury subsided,
liver regenerated, and animals rapidly recovered. Besides hepatic
support, engrafted cells provided paracrine factors, e.g., VEGF,
FGFs, G-CSF, etc., for hepatic protection and promotion of liver
regeneration [5,6]. Liver recovered due to proliferation of native
cells since transplanted cells in the liver did not proliferate [5].
Use of absorbable scaffolds for cell engraftment in peritoneal cav-
ity has long been without complications in animals and this
should not interfere with further surgery if needed. The role of
paracrine factors in rescue of ALF was supported by studies with
other cell types, e.g. transplantation of mouse endothelial pro-
genitor cells secreting another hepatoprotective cytokine, cardio-
trophin-1 [7]. This is signiﬁcant since endothelial cells have
increasingly been recognized to contribute in liver regeneration.
Recently, pigs with ALF were rescued by intraportal transplan-
tation of human bone marrow-derived mesenchymal cells, per-
haps with hepatic transdifferentiation [8], although more
studies are needed to conﬁrm this possibility. Interestingly, com-
parison of adult, fetal, and embryonic stem cell-derived mouse
hepatocytes indicated that adult hepatocytes most effectively
rescued mice in ALF [9].Future perspectives
Remarkably, studies of non-heart-beating (NHB) donor animals
as new sources of hepatocytes, showed the liver remained intact
long after death [10]. Despite molecular lesions, hepatocytes from
NHB donors did engraft and proliferate in animals. Another donor
source could be stem cells with highly efﬁcient protocols for
hepatic differentiation. Tissue engineering with decellularized–
recellularized substrates incorporating relevant cell types should
advance further directions for cell therapy (Fig. 1). Transplanta-Journal of Hepatology 201tion of hepatocytes along with other cell types, e.g. endothelial
cells, may be helpful.Conﬂict of interest
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